Connor, Clark & Lunn Investment Management Ltd. Eton Pharmaceuticals, Inc. Transaction History
Connor, Clark & Lunn Investment Management Ltd.
- $20 Billion
- Q4 2024
A detailed history of Connor, Clark & Lunn Investment Management Ltd. transactions in Eton Pharmaceuticals, Inc. stock. As of the latest transaction made, Connor, Clark & Lunn Investment Management Ltd. holds 214,878 shares of ETON stock, worth $3.14 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
214,878
Previous 65,014
230.51%
Holding current value
$3.14 Million
Previous $390,000
624.36%
% of portfolio
0.01%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding ETON
# of Institutions
74Shares Held
13.1MCall Options Held
284KPut Options Held
4.2K-
Opaleye Management Inc. Boston, MA2.85MShares$41.7 Million7.38% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA1.83MShares$26.7 Million1.12% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT1.12MShares$16.3 Million0.74% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.06MShares$15.5 Million0.0% of portfolio
-
Westside Investment Management, Inc.575KShares$8.4 Million1.61% of portfolio
About Eton Pharmaceuticals, Inc.
- Ticker ETON
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,297,000
- Market Cap $370M
- Description
- Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for th...